CD4 and colorectal cancer: Increasing evidence confirmed that administration with DEX was associated with improved postoperative immunosuppression, as reflected by the increased CD4+:CD8+ ratio and Th1:Th2 ratio (42, 43), and the results were also confirmed in the patients with colorectal cancer (38, 44).